HOUSTON, Nov. 13, 2018 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — AngioSoma (OTC: SOAN), a leading biotechnology research and development company, announces today the execution of a letter of intent to pursue a relationship with Biomedix®.
Biomedix® manufactures a noninvasive device, PADnet, that diagnoses Peripheral Artery Disease (PAD) in patients. Biomedix has over 1,000 PADnet devices under service throughout the United States and can potentially assist in our clinical trials and research, once we determine the scope and breadth of the services needed. We could potentially engage with Biomedix to:
1. Leverage PADnet technology, but using doctors and patients managed by another clinical research partner
2. Leverage PADnet technology through doctors willing to participate, that meets our specifications, such as geography and medical specialty, to assist in the trials
3. Leverage PADnet technology through identified patients willing to participate, that meets our specifications, such as disease severity and associated risk factors, to assist with the trials
AngioSoma intends to use the PADnet device to select patients for clinical trials and determine the presence and severity of PAD in patients before and after using Liprostin™, its flagship patented pharmaceutical intervention for PAD. Liprostin™ is currently in the approval process of the FDA for marketing. Combining these tightly aligned products will assist doctors in providing the best care possible and give patients peace of mind that interventions are working.
“It’s a natural fit for us,” said Alex Blankenship, President of AngioSoma. “The ability to verify the effectiveness of treatment by testing before and after interventions will enhance our efficacy data, leading to greater visibility for our products going forward.”
You can view the letter of intent by clicking here.
You can view and purchase products on Amazon.com: Go to Amazon Now
Also, products can be found on our ecommerce site: YouthfulBrilliance.com.
ABOUT ANGIOSOMA, INC.
AngioSoma, Inc. (https://angiosoma.com), a Nevada corporation based in Houston, Texas, is dedicated to improving the mental and physical wellbeing of men and women. To accomplish that purpose, we are launching a line of supplements under our SomaCeuticals™ common identity. Our supplements cover three industry segments: nutraceuticals, cosmeceuticals, and pharmaceuticals.
NOTICE REGARDING FORWARD LOOKING STATEMENTS
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words “believes,” “expects,” “anticipate” or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the company to differ materially from those expressed or implied by such forward-looking statements.
Contacts AngioSoma, Inc. Alex Blankenship investors@AngioSoma.com
